Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;39(2):216-224.
doi: 10.1007/s10875-019-00613-8. Epub 2019 Mar 26.

Nasal Nitric Oxide in Primary Immunodeficiency and Primary Ciliary Dyskinesia: Helping to Distinguish Between Clinically Similar Diseases

Affiliations

Nasal Nitric Oxide in Primary Immunodeficiency and Primary Ciliary Dyskinesia: Helping to Distinguish Between Clinically Similar Diseases

Zofia N Zysman-Colman et al. J Clin Immunol. 2019 Feb.

Abstract

Purpose: Primary ciliary dyskinesia (PCD) is a rare disorder of the mucociliary clearance leading to recurrent upper and lower respiratory tract infections. PCD is difficult to clinically distinguish from other entities leading to recurrent oto-sino-pulmonary infections, including primary immunodeficiency (PID). Nasal nitric oxide (nNO) is a sensitive and specific diagnostic test for PCD, but it has not been thoroughly examined in PID. Past publications have suggested an overlap in nNO levels among subjects with PCD and PID. We sought to determine if nNO measurements among patients diagnosed with PID would fall significantly above the established PCD diagnostic cutoff value of 77 nL/min.

Methods: Children > 5 years old and adults with definitive PID or PCD diagnoses were recruited from outpatient subspecialty clinics. Participants underwent nNO testing by standardized protocol using a chemiluminescence analyzer and completed a questionnaire concerning their chronic oto-sino-pulmonary symptoms, including key clinical criteria specific to diagnosed PCD (neonatal respiratory distress at term birth, year-round cough or nasal congestion starting before 6 months of age, any organ laterality defect).

Results: Participants included 32 patients with PID, 27 patients with PCD, and 19 healthy controls. Median nNO was 228.9.1 nL/min in the PID group, 19.7 nL/min in the PCD group, and 269.4 in the healthy controls (p < 0.0001). Subjects with PCD were significantly more likely to report key clinical criteria specific to PCD, but approximately 25% of PID subjects also reported at least 1 of these key clinical criteria (mainly year-round cough or nasal congestion).

Conclusions: While key clinical criteria associated with PCD often overlap with the symptoms reported in PID, nNO measurement by chemiluminescence technology allows for effective discrimination between PID and PCD.

Keywords: Primary ciliary dyskinesia; nasal nitric oxide; primary immunodeficiency.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors declare no conflicts of interest with regards to the publication of this paper.

Figures

Fig 1
Fig 1
Initial nNO in primary immunodeficiency, PCD and healthy controls were compared using a Kruskal-Wallis test with post-hoc pairwise Mann-Whitney U tests. Horizontal lines represent the group median. Dashed line represents the PCD diagnostic cut-off of 77 nL/min. ****p < 0.0001. Only two PCD subjects (both with pathogenic variants in RSPH1) had initial or repeat nNO values above the PCD diagnostic cutoff of 77 nL/min (solid black horizontal line). This is consistent with previous observations that pathogenic variants in RSPH1 can sometimes result in nNO measurements above the diagnostic cutoff [29]. Two PID subjects initially had nNO measurements below the diagnostic cutoff of 77nL/min. Both of these subjects eventually had nNO measurements that rose above 77 nL/min, though one subject with RAG1 immunodeficiency had repeat nNO values fall below this cutoff.
Fig 2
Fig 2
CVID – Common variable immunodeficiency, hypogam – hypogammaglobulinemia, PAD-polysaccharide antibody deficiency, MBL – Mannose binding lectin deficiency, XLA – X-linked agammaglobulinemia, CD – complement deficiency
Fig 3
Fig 3
One PCD subject with RSPH1 and longitudinal measurements mutation had one of three values above the diagnostic cutoff of 77 nL/min. As noted, this is consistent with observations that RSPH1 mutations can occasionally generate nNO measurements above 77 nL/min.

Similar articles

Cited by

References

    1. Leigh MW, O’Callaghan C, Knowles MR. The Challenges of Diagnosing Primary Ciliary Dyskinesia. Proceedings of the American Thoracic Society. 2011;8(5):434–7. doi:10.1513/pats.201103-028SD. - DOI - PMC - PubMed
    1. Shapiro AJ, Zariwala MA, Ferkol T, Davis SD, Sagel SD, Dell SD et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatric Pulmonology. 2016;51(2):115–32. doi:10.1002/ppul.23304. - DOI - PMC - PubMed
    1. Leigh MW, Ferkol TW, Davis SD, Lee HS, Rosenfeld M, Dell SD et al. Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents. Ann Am Thorac Soc 2016;13(8):1305–13. doi:10.1513/AnnalsATS.201511-748OC. - DOI - PMC - PubMed
    1. Kouis P, Yiallouros PK, Middleton N, Evans JS, Kyriacou K, Papatheodorou SI. Prevalence of primary ciliary dyskinesia in consecutive referrals of suspect cases and the transmission electron microscopy detection rate: a systematic review and meta-analysis. Pediatr Res 2017;81(3):398–405. doi:10.1038/pr.2016.263. - DOI - PubMed
    1. Zariwala MA, Knowles MR, Leigh MW. Primary Ciliary Dyskinesia In: MP A HH A RA P, editors. GeneReviews. Seattle: University of Wahington; 2007. [updated 2015 Sept 3].

Publication types

LinkOut - more resources